• Explore /
  • Poster
  • / Final overall survival analysis and organ-specific target lesion assessments with two-year follow-up in CheckMate 9ER: Nivolumab plus cabozantinib versus sunitinib for patients with advanced renal cell carcinoma.

Final overall survival analysis and organ-specific target lesion assessments with two-year follow-up in CheckMate 9ER: Nivolumab plus cabozantinib versus sunitinib for patients with advanced renal cell carcinoma.

Abstract Video & Slides Poster

Authors

null

Thomas Powles

Barts Cancer Institute, Cancer Research UK Experimental Cancer Medicine Centre, Queen Mary University of London, London, United Kingdom

Thomas Powles , Toni K. Choueiri , Mauricio Burotto , Bernard Escudier , Maria Teresa Bourlon , Amishi Yogesh Shah , Cristina Suárez , Alketa Hamzaj , Camillo Porta , Christopher Hocking , Elizabeth R Kessler , Howard Gurney , Yoshihiko Tomita , Jens Bedke , Joshua Zhang , Burcin Simsek , Christian Scheffold , Andrea B. Apolo , Robert J. Motzer

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral, and Testicular Cancers

Track

Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer,Urethral Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT03141177

Citation

J Clin Oncol 40, 2022 (suppl 6; abstr 350)

DOI

10.1200/JCO.2022.40.6_suppl.350

Abstract #

350

Poster Bd #

F12

Abstract Disclosures

Similar Posters

First Author: Robert J. Motzer

First Author: Jens Bedke

First Author: Kevin Yan

First Author: Philippe Barthelemy